Picture of Prelude Therapeutics Incorporated logo

PRLD — Prelude Therapeutics Incorporated News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Prelude Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

* Prelude Therapeutics Inc  PRLD.OQ  reported a quarterly
adjusted
loss of 42 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -58 cents.  The mean expectation of
four analysts for the quarter was for a loss of 48 cents per
share. Wall Street expected results to range from -55 cents
to -44 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Prelude Therapeutics Inc's reported EPS for the quarter
was a
loss of 42 cents​.
    * The company reported a quarterly loss of $31.43 million.
    * Prelude Therapeutics Inc shares had fallen by 19.2% this
quarter and lost 10.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 385%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Prelude
Therapeutics Inc is $5.00 
This summary was machine generated from LSEG data May 7 at 12:02
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.48          -0.42          Beat
 Dec. 31 2023      -0.49          -0.46          Beat
 Sep. 30 2023      -0.58          -0.45          Beat
 Jun. 30 2023      -0.63          -0.54          Beat

Recent news on Prelude Therapeutics Incorporated

See all news